Diligence memo · auto-generated · as of July 2, 2026
Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Acadia Pharmaceuticals Inc operates in Pharmaceuticals, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Acadia Pharmaceuticals Inc has raised $107M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $86M on 2012-12-17.
Most recent recorded round closed around 2012-12-17.
Valuation (modeled)modeled
Provath models Acadia Pharmaceuticals Inc at approximately $3.0B (range $281M–$8.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.69× the median modeled value of Series C Pharmaceuticals companies in 2010–2012 (12 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 23 months.
Last raise 13.5 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 91% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Agios Pharmaceuticals Inc, Merrimack Pharmaceuticals Inc, PCAS Patient Care Automation Services Inc., China Medicine Corp, Brickell Bay Acquisition Corp..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.